GlassScriptPhysician profile
Julena D Adams
NPI 1669533295
$11,238.37
in general payments reported to CMS, 2019-2025
34 companies · $3,068 in 2025
The $3,068 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,113 · 2022: $2,172 · 2023: $2,276 · 2024: $2,610 · 2025: $3,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,458 · Education: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,458.33 |
| Education | $494.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,786.20 | 2021-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,582.63 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Lilly USA, LLC | $813.49 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $802.25 | 2021-2025 | Dupixent, Libtayo |
| Amgen INC. | $741.07 | 2021-2025 | Otezla, Otezla |
| Leo Pharma INC. | $615.58 | 2021-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $571.15 | 2022-2025 | Sotyktu, Sprycel |
| Sun Pharmaceutical Industries INC. | $495.93 | 2021-2025 | Winlevi, Absorica Ld, Odomzo |
| Genzyme Corporation | $463.57 | 2021-2025 | |
| Pfizer INC. | $394.13 | 2021-2025 | |
| Ucb, INC. | $331.48 | 2021-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $308.06 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $278.08 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $272.82 | 2022-2025 | Spevigo, Cyltezo |
| Dermavant Sciences, INC. | $247.99 | 2023-2024 | Vtama |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $234.12 | 2021-2025 | Klisyri, Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $209.44 | 2021-2025 | Cabtreo, Jublia, Siliq |
| Incyte Corporation | $183.52 | 2021-2024 | Opzelura |
| Galderma Laboratories, L.P. | $166.80 | 2022-2025 | Aklief |
| Epi Health, LLC | $121.93 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $96.99 | 2025 | |
| Biofrontera INC. | $91.72 | 2022-2025 | Ameluz, Rhodoled Xl, Xepi |
| Vyne Pharmaceuticals INC. | $90.36 | 2021 | |
| Stemline Therapeutics INC. | $83.59 | 2021 | |
| Lnhc, INC | $46.66 | 2025 | Zelsuvmi |
| Convatec INC. | $40.36 | 2024 | |
| Organogenesis INC. | $38.43 | 2024-2025 | Via Matrix, Novachor |
| Genentech USA, INC. | $27.13 | 2023-2024 | Xolair, Erivedge |
| Journey Medical Corporation | $21.36 | 2025 | |
| Sebela Pharmaceuticals INC. | $18.07 | 2021 | |
| Blueprint Medicines Corporation | $17.29 | 2022 | |
| Fresenius Kabi USA, LLC | $17.10 | 2023 | Idacio |
| Verrica Pharmaceuticals INC. | $15.90 | 2024 | Ycanth |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julena Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.